BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 15765180)

  • 1. beta-Blocker use, BMD, and fractures in the study of osteoporotic fractures.
    Reid IR; Gamble GD; Grey AB; Black DM; Ensrud KE; Browner WS; Bauer DC
    J Bone Miner Res; 2005 Apr; 20(4):613-8. PubMed ID: 15765180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study.
    Pasco JA; Henry MJ; Sanders KM; Kotowicz MA; Seeman E; Nicholson GC;
    J Bone Miner Res; 2004 Jan; 19(1):19-24. PubMed ID: 14753732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of low BMD for 1-year fracture outcomes is similar for postmenopausal women ages 50-64 and 65 and Older: results from the National Osteoporosis Risk Assessment (NORA).
    Siris ES; Brenneman SK; Miller PD; Barrett-Connor E; Chen YT; Sherwood LM; Abbott TA
    J Bone Miner Res; 2004 Aug; 19(8):1215-20. PubMed ID: 15231007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures.
    Stone KL; Seeley DG; Lui LY; Cauley JA; Ensrud K; Browner WS; Nevitt MC; Cummings SR;
    J Bone Miner Res; 2003 Nov; 18(11):1947-54. PubMed ID: 14606506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum retinoids and beta-carotene as predictors of hip and other fractures in elderly women.
    Barker ME; McCloskey E; Saha S; Gossiel F; Charlesworth D; Powers HJ; Blumsohn A
    J Bone Miner Res; 2005 Jun; 20(6):913-20. PubMed ID: 15883630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 10-year probability of recurrent fractures following wrist and other osteoporotic fractures in a large clinical cohort: an analysis from the Manitoba Bone Density Program.
    Hodsman AB; Leslie WD; Tsang JF; Gamble GD
    Arch Intern Med; 2008 Nov; 168(20):2261-7. PubMed ID: 19001204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effect of beta blockers in postmenopausal women: influence on fractures, bone density, micro and macroarchitecture.
    Bonnet N; Gadois C; McCloskey E; Lemineur G; Lespessailles E; Courteix D; Benhamou CL
    Bone; 2007 May; 40(5):1209-16. PubMed ID: 17324648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ApoE gene polymorphisms, BMD, and fracture risk in elderly men and women: the Rotterdam study.
    Schoofs MW; van der Klift M; Hofman A; van Duijn CM; Stricker BH; Pols HA; Uitterlinden AG
    J Bone Miner Res; 2004 Sep; 19(9):1490-6. PubMed ID: 15312249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of the G-174C variant in the interleukin-6 promoter region with bone loss and fracture risk in older women.
    Moffett SP; Zmuda JM; Cauley JA; Stone KL; Nevitt MC; Ensrud KE; Hillier TA; Hochberg MC; Joslyn G; Morin P; Cummings SR;
    J Bone Miner Res; 2004 Oct; 19(10):1612-8. PubMed ID: 15355555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low BMD is less predictive than reported falls for future limb fractures in women across Europe: results from the European Prospective Osteoporosis Study.
    Kaptoge S; Benevolenskaya LI; Bhalla AK; Cannata JB; Boonen S; Falch JA; Felsenberg D; Finn JD; Nuti R; Hoszowski K; Lorenc R; Miazgowski T; Jajic I; Lyritis G; Masaryk P; Naves-Diaz M; Poor G; Reid DM; Scheidt-Nave C; Stepan JJ; Todd CJ; Weber K; Woolf AD; Roy DK; Lunt M; Pye SR; O'neill TW; Silman AJ; Reeve J
    Bone; 2005 Mar; 36(3):387-98. PubMed ID: 15777673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aspirin and NSAID use in older women: effect on bone mineral density and fracture risk. Study of Osteoporotic Fractures Research Group.
    Bauer DC; Orwoll ES; Fox KM; Vogt TM; Lane NE; Hochberg MC; Stone K; Nevitt MC
    J Bone Miner Res; 1996 Jan; 11(1):29-35. PubMed ID: 8770694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of total hip bone area on osteoporosis diagnosis and fractures.
    Leslie WD; Tsang JF; Lix LM
    J Bone Miner Res; 2008 Sep; 23(9):1468-76. PubMed ID: 18442317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
    Seibel MJ; Naganathan V; Barton I; Grauer A
    J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population trends in BMD testing, treatment, and hip and wrist fracture rates: are the hip fracture projections wrong?
    Jaglal SB; Weller I; Mamdani M; Hawker G; Kreder H; Jaakkimainen L; Adachi JD
    J Bone Miner Res; 2005 Jun; 20(6):898-905. PubMed ID: 15883628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study.
    Garnero P; Cloos P; Sornay-Rendu E; Qvist P; Delmas PD
    J Bone Miner Res; 2002 May; 17(5):826-33. PubMed ID: 12009013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of osteopenic women at high risk of fracture: the OFELY study.
    Sornay-Rendu E; Munoz F; Garnero P; Duboeuf F; Delmas PD
    J Bone Miner Res; 2005 Oct; 20(10):1813-9. PubMed ID: 16160738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteoporosis and fracture risk in women of different ethnic groups.
    Barrett-Connor E; Siris ES; Wehren LE; Miller PD; Abbott TA; Berger ML; Santora AC; Sherwood LM
    J Bone Miner Res; 2005 Feb; 20(2):185-94. PubMed ID: 15647811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends and determinants of antiresorptive drug use for osteoporosis among elderly women.
    Perreault S; Dragomir A; Desgagné A; Blais L; Rossignol M; Blouin J; Moride Y; Ste-Marie LG; Fernandès JC
    Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):685-95. PubMed ID: 15645517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD.
    Watts NB; Geusens P; Barton IP; Felsenberg D
    J Bone Miner Res; 2005 Dec; 20(12):2097-104. PubMed ID: 16294263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.
    Siris ES; Harris ST; Eastell R; Zanchetta JR; Goemaere S; Diez-Perez A; Stock JL; Song J; Qu Y; Kulkarni PM; Siddhanti SR; Wong M; Cummings SR;
    J Bone Miner Res; 2005 Sep; 20(9):1514-24. PubMed ID: 16059623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.